This handy, accessible single volume presents useful clinical information to expose the pathophysiology underlying major pulmonary diseases, and traces the steps of treatment, from establishing diagnosis to managing therapy. Contains more than 400 summary tables, radiographs, pathology specimens, and other illustrations that encapsulate information and highlight key points! A suggested reading list accompanies each chapter to facilitate further study! Written by over 55 internationally recognized experts who provide personal experiences, observations, and review statements, and recommend action based on their expertise dealing with patients, Medical Management of Pulmonary Diseases assesses new, efficient, cost-effective technologies for asthma and for the delivery of oxygen therapy evaluates new directions in the diagnosis and treatment of cystic fibrosis, lung cancer, occupational lung diseases, and diffuse interstitial lung disease describes the anatomy and physiology of the respiratory tract and includes examples of abnormalities drawn from common respiratory diseases discusses standard therapies for most pulmonary disease patients as well as targeted management for specific cases addresses common diagnostic and treatment dilemmas and suggests helpful algorithms for care spotlights asthma, chronic obstructive pulmonary disease, sleep-disordered breathing, tuberculosis, and other conditions that warrant careful management follows the progression of lung cancer from initial diagnosis through staging, and explores individualized therapy options considers special environments that may contribute to respiratory symptoms details the effect pregnancy and surgery have on pulmonary disease and more! Medical Management of Pulmonary Diseases serves as an excellent user-friendly guide ideal for primary care, internal medicine, and family practice physicians; pulmonologists and pulmonary disease specialists; clinical allergists; immunologists; respiratory therapists; thoracic surgeons; physiologists; and medical school students in these disciplines.

Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.

Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries.

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

A panel of recognized authorities comprehensively review the medical, surgical, and pathophysiologic issues relevant to lung volume reduction surgery for emphysema. Topics range from the open technique and video-assisted thoracoscopic approaches to LVRS, to anesthetic management, to perioperative and nursing care of the patient. The experts also detail the selection of candidates for LVRS, the clinical results and clinical trials in LVRS, and the effects of LVRS on survival rates.

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.

Respiratory diseases affect millions of people each year and represent a major health burden around the world. This timely reference surveys and evaluates the drug treatments available for the main categories of lung diseases including asthma, tuberculosis, chronic obstructive pulmonary disease, lung cancer, and respiratory infections. The recent re-emergence of tuberculosis and the increase in asthma in certain populations underlines the importance of finding effective new treatments for these diseases. This publication, a comprehensive reference, is one of the first to survey current and novel drug treatments for this group of diseases. It is certain to establish itself as an essential source of reference for respiratory physicians, clinicians and clinical pharmacologists.